Assertio presents first-ever real-world study showing patient experience with sympazan® (clobazam) oral film, civ

Baltimore, sept. 15, 2025 (globe newswire) -- assertio holdings, inc. (“assertio” or the “company”) (nasdaq: asrt), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced new data from a first-ever real-world study of sympazan (clobazam) oral film.
ASRT Ratings Summary
ASRT Quant Ranking